Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Enforcement Targets Probiotic Products, Spanish Language Advertising

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission will crack down on advertising for probiotic products that overstate immunity claims, an FTC official said
Advertisement

Related Content

Embria Expands Market Reach For EpiCor Through Local Government
Dannon's FTC Settlement Requires FDA Approval For Cold/Flu Immunity Claims
Probiotic Firms Must Overcome Barriers To Cash In On High Growth
FTC's First Probiotic Claims Case Emphasizes Need For Well-Designed Studies
Phillips Probiotic Recognizes Bacteria's Strength Is In Numbers
Omega-3 Probe Underscores FTC Standard For Claims Substantiation
FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims
Dannon's DanActive And Activia Not Immune To Health Claim Scrutiny
Dannon's DanActive And Activia Not Immune To Health Claim Scrutiny
FTC Settlement Looks To Ground Airborne Claims

Topics

Advertisement
UsernamePublicRestriction

Register

PS104153

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel